{
  "abstract": "Introduction Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Metabolic dysfunction-associated steatohepatitis (MASH), has become one of the fastest growing risk factors of HCC in the US. While clinical evidence indicates that MASH predisposes an individual to HCC development, the strength and relative impact of this relationship with respect to other underlying etiologies is less well understood.Methods A matched case-control study was conducted using SEER-Medicare linked data from October 2015 through December 2020. Eligible controls (non-HCC cases) were matched to cases using k:1 exact matching without replacement based on birth year, race/ethnicity, and sex. Control index date was assigned as the HCC diagnosis date of their matched case. MASH was defined using the K75.81 ICD-10 code, with exposure status ascertained during the 36-months prior to a patient’s index date. This interval additionally served as the washout and baseline period for covariate measurement and application of inclusion/exclusion criteria. Logistic regression with robust standard errors was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (CI) controlling for matching factors (race/ethnicity, sex, birth year) and obesity, diabetes, cirrhosis, and index year.Results A total of 4,875 HCC cases were matched to 5,030 controls from a 5% random subsample of non-cancer Medicare beneficiaries. Exposure status was heavily skewed, with MASH identified in 5% of HCC cases and only 0.1% of non-cancer controls. MASH was found to be significantly associated with a 4.88-fold (95% CI: 1.36 - 17.5, p < 0.001) increase in the odds of HCC development relative to non-MASH patients over the study period.Conclusions In this analysis, clinically rich SEER-Medicare data were used to generate additional insight into the relationship between MASH and HCC development. Results suggesting that MASH patients are at a higher risk of HCC relative to patients with other precipitating liver conditions highlight the importance of expanded surveillance and effective treatment in reducing the clinical burden of HCC in the MASH population.",
  "authors": [
    {
      "affiliations": [
        "Madrigal Pharmaceuticals, West Conshohocken, United States"
      ],
      "name": "Yestle Kim"
    },
    {
      "affiliations": [
        "Medicus Economics, LLC, Milton, United States"
      ],
      "name": "Samantha Clark"
    },
    {
      "affiliations": [
        "Medicus Economics, LLC, Milton, United States"
      ],
      "name": "Arushi Chadha"
    },
    {
      "affiliations": [
        "Medicus Economics, LLC, Milton, United States"
      ],
      "name": "Eric Zuk"
    },
    {
      "affiliations": [
        "Robert G Gish Consultants LLC, La Jolla, United States"
      ],
      "name": "Robert G Gish"
    }
  ],
  "title": "P76 Role of metabolic dysfunction-associated steatohepatitis as a risk factor for hepatocellular carcinoma development",
  "uid": "845b9606-a737-5614-803c-2b711f8e6a6d"
}